A Randomised, Open-label, Phase III Study to Evaluate the Efficacy and Safety of Oral Afatinib (BIBW 2992) Versus Intravenous Methotrexate in Patients With Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma Who Have Progressed After Platinum-based Therapy

Trial Profile

A Randomised, Open-label, Phase III Study to Evaluate the Efficacy and Safety of Oral Afatinib (BIBW 2992) Versus Intravenous Methotrexate in Patients With Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma Who Have Progressed After Platinum-based Therapy

Recruiting
Phase of Trial: Phase III

Latest Information Update: 14 Jul 2017

At a glance

  • Drugs Afatinib (Primary) ; Methotrexate
  • Indications Head and neck cancer
  • Focus Registrational; Therapeutic Use
  • Acronyms LUX-Head and Neck-3
  • Sponsors Boehringer Ingelheim Pharmaceuticals
  • Most Recent Events

    • 18 Apr 2017 Planned End Date changed from 1 Jun 2019 to 28 Nov 2018.
    • 14 Feb 2017 Planned End Date changed from 1 Dec 2018 to 1 Jun 2019.
    • 14 Feb 2017 Planned primary completion date changed from 1 Aug 2017 to 1 Feb 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top